Terminated PHASE1 INTERVENTIONAL 2-arm NCT02589340

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia (BUS-PD)

Sponsor: Oregon Health and Science University

Conditions Dyskinesias Movement Disorders Parkinson's Disease

Updated 8 times since 2017 Last updated: Mar 3, 2021 Started: Jan 31, 2016 Primary completion: Feb 23, 2021 Completion: Feb 23, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment

Other terminated trials from Oregon Health and Science University

More terminations from Oregon Health and Science University

A PHASE1 clinical study on Dyskinesias and Movement Disorders, this trial is terminated or withdrawn. The trial is conducted by Oregon Health and Science University and has accumulated 8 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Apr 2021 — Jul 2024 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE1
Apr 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

May 2019 — Apr 2020 [monthly]

Recruiting PHASE1
Jun 2018 — May 2019 [monthly]

Recruiting PHASE1
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oregon Health and Science University
Portland VA Medical Center

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States